recombinate 500 iu
teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.
eloctate 1000
sanofi - aventis israel ltd - coagulation factor viii - powder and solvent for solution for injection - coagulation factor viii 1000 iu - coagulation factor vii - eloctate [antihemophilic factor (recombinant fc fusion protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with hemophilia a (congenital factor viii deficiency) for:• control and prevention of bleeding episodes.• routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• perioperative management (surgical prophylaxis).eloctate is not indicated for the treatment of von willebrand disease.
eloctate 250
sanofi - aventis israel ltd - coagulation factor viii - powder and solvent for solution for injection - coagulation factor viii 250 iu - coagulation factor vii - eloctate [antihemophilic factor (recombinant fc fusion protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children12 years of age and older with hemophilia a (congenital factor viii deficiency) for:• control and prevention of bleeding episodes.• routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• perioperative management (surgical prophylaxis).eloctate is not indicated for the treatment of von willebrand disease.
eloctate 500
sanofi - aventis israel ltd - coagulation factor viii - powder and solvent for solution for injection - coagulation factor viii 500 iu - coagulation factor vii - eloctate [antihemophilic factor (recombinant fc fusion protein)] is a long-acting antihemophilic factor (recombinant) indicated in adults and children 12 years of age and older with hemophilia a (congenital factor viii deficiency) for:• control and prevention of bleeding episodes.• routine prophylaxis to prevent or reduce the frequency of bleeding episodes.• perioperative management (surgical prophylaxis).eloctate is not indicated for the treatment of von willebrand disease.
koate dvi 1000 iu vial powder for solution for injection
grifols therapeutics inc, united states - omfiloctocog alfa - powder for solution for injection - 1000 iu
koate dvi 250 iu vial powder for solution for injection
grifols therapeutics inc, united states - omfiloctocog alfa - powder for solution for injection - 250 iu
koate dvi 500 iu vial powder for solution for injection
grifols therapeutics inc, united states - omfiloctocog alfa - powder for solution for injection - 500 iu
novo seven 1.2mg-vial solution for injection
novo nordisk - eptacog alfa - solution for injection - 1.2 mg
novo seven 2.4mg-vial solution for injection
novo nordisk - eptacog alfa - solution for injection - 2.4 mg
novo seven 4.8mg-vial solution for injection
novo nordisk - eptacog alfa - solution for injection - 4.8 mg